{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:14:46Z","timestamp":1783440886012,"version":"3.54.6"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","award":["114024118"],"award-info":[{"award-number":["114024118"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inflammatory disorders like diabetes, systemic lupus erythematodes, inflammatory lung diseases, rheumatoid arthritis and multiple sclerosis, but also rejection of transplanted organs and GvHD, form a major burden of disease. Current classes of immune suppressive drugs to treat these disorders are never curative and side effects are common. Therefore there is a need for new drugs with improved and more targeted modes of action. Potential candidates are the DNA methyl transferase inhibitor 5-azacytidine (Aza) and its derivative 5-aza 2\u2032deoxycitidine (DAC). Aza and DAC have been tested in several pre-clinical in vivo studies. In order to obtain an overview of disorders for which Aza and\/or DAC can be a potential treatment, and to find out where information is lacking, we systematically reviewed pre-clinical animal studies assessing Aza or DAC as a potential therapy for distinct inflammatory disorders. Also, study quality and risk of bias was systematically assessed. In the 35 identified studies, we show that both Aza and DAC do not only seem to be able to alleviate a number of inflammatory disorders, but also prevent solid organ rejection and GvHD in in vivo pre-clinical animal models. Aza\/DAC are known to upregulate FOXP3, a master transcription factor for Treg, in vitro<jats:italic>.<\/jats:italic> Seventeen studies described the effect on Treg, of which 16 studies showed an increase in Treg. Increasing Treg therefore seems to be a common mechanism in preventing inflammatory disorders by Aza\/DAC. We also found, however, that many essential methodological details were poorly reported leading to an unclear risk of bias. Therefore, reported effects might be an overestimation of the true effect.<\/jats:p>","DOI":"10.1186\/s12967-020-02615-2","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T19:04:06Z","timestamp":1609959846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immune responses to azacytidine in animal models of inflammatory disorders: a systematic review"],"prefix":"10.1186","volume":"19","author":[{"given":"Sija","family":"Landman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiel","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet E. J.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1210-7502","authenticated-orcid":false,"given":"Hans J. P. M.","family":"Koenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"4","key":"2615_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/08916930802024616","volume":"41","author":"FM Strickland","year":"2008","unstructured":"Strickland FM, Richardson BC. Epigenetics in human autoimmunity. Epigenetics in autoimmunity\u2014DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity. 2008;41(4):278\u201386.","journal-title":"Autoimmunity."},{"issue":"7","key":"2615_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.4161\/epi.25201","volume":"8","author":"B Suarez-Alvarez","year":"2013","unstructured":"Suarez-Alvarez B, Baragano Raneros A, Ortega F, Lopez-Larrea C. Epigenetic modulation of the immune function: a potential target for tolerance. Epigenetics. 2013;8(7):694\u2013702.","journal-title":"Epigenetics"},{"issue":"1","key":"2615_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8\u201313.","journal-title":"Int J Cancer"},{"issue":"1","key":"2615_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/hdy.2010.54","volume":"105","author":"ER Gibney","year":"2010","unstructured":"Gibney ER, Nolan CM. Epigenetics and gene expression. Heredity. 2010;105(1):4\u201313.","journal-title":"Heredity"},{"issue":"6","key":"2615_CR5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/cam4.321","volume":"3","author":"SK Sadashiv","year":"2014","unstructured":"Sadashiv SK, Hilton C, Khan C, Rossetti JM, Benjamin HL, Fazal S, et al. Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia. Cancer Med. 2014;3(6):1570\u20138.","journal-title":"Cancer Med"},{"issue":"1","key":"2615_CR6","doi-asserted-by":"publisher","first-page":"e2014020","DOI":"10.4084\/mjhid.2014.020","volume":"6","author":"A Tendas","year":"2014","unstructured":"Tendas A, Cupelli L, Siniscalchi A, Scaramucci L, Giovannini M, Dentamaro T, et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Mediter J Hematol Infect Dis. 2014;6(1):e2014020.","journal-title":"Mediter J Hematol Infect Dis"},{"issue":"11","key":"2615_CR7","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","volume":"116","author":"O Goodyear","year":"2010","unstructured":"Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116(11):1908\u201318.","journal-title":"Blood"},{"issue":"6","key":"2615_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/2040620712464882","volume":"3","author":"C Khan","year":"2012","unstructured":"Khan C, Pathe N, Fazal S, Lister J, Rossetti JM. Azacitidine in the management of patients with myelodysplastic syndromes. Therapeutic advances in hematology. 2012;3(6):355\u201373.","journal-title":"Therapeutic advances in hematology"},{"issue":"8","key":"2615_CR9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3324\/haematol.2012.074823","volume":"98","author":"B Costantini","year":"2013","unstructured":"Costantini B, Kordasti SY, Kulasekararaj AG, Jiang J, Seidl T, Abellan PP, et al. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica. 2013;98(8):1196\u2013205.","journal-title":"Haematologica"},{"issue":"9","key":"2615_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10(9):1000\u20137.","journal-title":"Nat Immunol"},{"issue":"6","key":"2615_CR11","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2008-01-133967","volume":"112","author":"HJ Koenen","year":"2008","unstructured":"Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008;112(6):2340\u201352.","journal-title":"Blood"},{"issue":"1","key":"2615_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4049\/jimmunol.182.1.259","volume":"182","author":"G Lal","year":"2009","unstructured":"Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol (Baltimore, Md: 1950). 2009;182(1):259\u201373.","journal-title":"J Immunol (Baltimore, Md: 1950)."},{"issue":"3","key":"2615_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/imm.12261","volume":"142","author":"J Kehrmann","year":"2014","unstructured":"Kehrmann J, Tatura R, Zeschnigk M, Probst-Kepper M, Geffers R, Steinmann J, et al. Impact of 5-aza-2\u2019-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells. Immunology. 2014;142(3):384\u201395.","journal-title":"Immunology"},{"issue":"6","key":"2615_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.coi.2010.08.012","volume":"22","author":"GL Cvetanovich","year":"2010","unstructured":"Cvetanovich GL, Hafler DA. Human regulatory T cells in autoimmune diseases. Curr Opin Immunol. 2010;22(6):753\u201360.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2615_CR15","doi-asserted-by":"publisher","first-page":"e00007","DOI":"10.1002\/ebm2.7","volume":"2","author":"RBM de Vries","year":"2015","unstructured":"de Vries RBM, Hooijmans CR, Langendam MW, van Luijk J, Leenaars M, Ritskes-Hoitinga M, et al. A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evid Based Preclin Med. 2015;2(1):e00007.","journal-title":"Evid Based Preclin Med"},{"issue":"1","key":"2615_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/0023677213494374","volume":"48","author":"RB de Vries","year":"2014","unstructured":"de Vries RB, Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M. Updated version of the Embase search filter for animal studies. Lab Anim. 2014;48(1):88.","journal-title":"Lab Anim"},{"issue":"3","key":"2615_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1258\/la.2010.009117","volume":"44","author":"CR Hooijmans","year":"2010","unstructured":"Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M. Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed. Lab Anim. 2010;44(3):170\u20135.","journal-title":"Lab Anim"},{"key":"2615_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"2615_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S0171-2985(11)80008-2","volume":"162","author":"E Paluska","year":"1982","unstructured":"Paluska E, Hruba A, Madar J, Cinatl J, Chudomel V, Nezvalova J, et al. Inhibitory effects of 5-azapyrimidine nucleosides on cellular immunity. Immunobiology. 1982;162(3):288\u201396.","journal-title":"Immunobiology"},{"key":"2615_CR20","first-page":"99","volume":"2","author":"K Sula","year":"1987","unstructured":"Sula K, Nouza K, Madar J, Cihak A. Modulation of cell-mediated immunity with 5-azapyrimidine nucleosides. Czechoslov Med. 1987;2:99\u2013108.","journal-title":"Czechoslov Med"},{"issue":"1","key":"2615_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","volume":"115","author":"LI Sanchez-Abarca","year":"2010","unstructured":"Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115(1):107\u201321.","journal-title":"Blood"},{"key":"2615_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","volume":"1","author":"J Choi","year":"2010","unstructured":"Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;1:129\u201339.","journal-title":"Blood"},{"key":"2615_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-016-0281-2","volume":"1","author":"G Fransolet","year":"2016","unstructured":"Fransolet G, Ehx G, Somja J, Delens L, Hannon M, Muller J, et al. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. J Hematol Oncol. 2016;1:53.","journal-title":"J Hematol Oncol"},{"key":"2615_CR24","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.4049\/jimmunol.1502399","volume":"9","author":"ML Cooper","year":"2017","unstructured":"Cooper ML, Choi J, Karpova D, Vij K, Ritchey J, Schroeder MA, et al. Azacitidine mitigates graft-versus-host disease via differential effects on the proliferation of T effectors and natural regulatory T cells in vivo. J Immunol (Baltimore, Md: 1950). 2017;9:3746\u201354.","journal-title":"J Immunol (Baltimore, Md: 1950)."},{"key":"2615_CR25","doi-asserted-by":"publisher","first-page":"e1314425","DOI":"10.1080\/2162402X.2017.1314425","volume":"5","author":"G Ehx","year":"2017","unstructured":"Ehx G, Fransolet G, de Leval L, Hondt S, Lucas S, Hannon M, et al. Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology. 2017;5:e1314425.","journal-title":"Oncoimmunology"},{"issue":"4","key":"2615_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/imm.12343","volume":"143","author":"C Cheng","year":"2014","unstructured":"Cheng C, Wang S, Ye P, Huang X, Liu Z, Wu J, et al. \u201cDefault\u201d generated neonatal regulatory T cells are hypomethylated at conserved non-coding sequence 2 and promote long-term cardiac allograft survival. Immunology. 2014;143(4):618\u201330.","journal-title":"Immunology"},{"key":"2615_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.trim.2013.10.001","volume":"1\u20134","author":"H Guo","year":"2013","unstructured":"Guo H, Wang W, Zhao N, He X, Zhu L, Jiang X. Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice. Transpl Immunol. 2013;1\u20134:99\u2013104.","journal-title":"Transpl Immunol"},{"key":"2615_CR28","doi-asserted-by":"publisher","first-page":"56802","DOI":"10.18632\/oncotarget.18063","volume":"34","author":"X Wang","year":"2017","unstructured":"Wang X, Wang J, Yu Y, Ma T, Chen P, Zhou B, et al. Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models. Oncotarget. 2017;34:56802\u201315.","journal-title":"Oncotarget"},{"key":"2615_CR29","doi-asserted-by":"publisher","first-page":"e104022","DOI":"10.1371\/journal.pone.0104022","volume":"8","author":"N Uchida","year":"2014","unstructured":"Uchida N, Hsieh MM, Platner C, Saunthararajah Y, Tisdale JF. Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction. PLoS ONE. 2014;8:e104022.","journal-title":"PLoS ONE"},{"key":"2615_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.trim.2013.01.005","volume":"2\u20133","author":"J Hong","year":"2013","unstructured":"Hong J, Yeom HJ, Lee E, Han KH, Koo TY, Cho B, et al. Islet allograft rejection in sensitized mice is refractory to control by combination therapy of immune-modulating agents. Transpl Immunol. 2013;2\u20133:86\u201392.","journal-title":"Transpl Immunol"},{"issue":"4","key":"2615_CR31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.transci.2017.07.005","volume":"56","author":"E Cozzi","year":"2017","unstructured":"Cozzi E, Colpo A, De Silvestro G. The mechanisms of rejection in solid organ transplantation. Transfus Apheres Sci. 2017;56(4):498\u2013505.","journal-title":"Transfus Apheres Sci"},{"issue":"9674","key":"2615_CR32","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet (London, England). 2009;373(9674):1550\u201361.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2615_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cnur.2015.10.008","volume":"51","author":"TL Allison","year":"2016","unstructured":"Allison TL. Immunosuppressive therapy in transplantation. Nurs Clin North Am. 2016;51(1):107\u201320.","journal-title":"Nurs Clin North Am"},{"issue":"12","key":"2615_CR34","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00109-009-0530-8","volume":"87","author":"Q Zheng","year":"2009","unstructured":"Zheng Q, Xu Y, Liu Y, Zhang B, Li X, Guo F, et al. Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice. J Mol Med (Berlin, Germany). 2009;87(12):1191\u2013205.","journal-title":"J Mol Med (Berlin, Germany)"},{"key":"2615_CR35","first-page":"e87748","volume":"19","author":"X Wang","year":"2016","unstructured":"Wang X, Cao Q, Yu L, Shi H, Xue B, Shi H. Epigenetic regulation of macrophage polarization and inflammation by DNA methylation in obesity. JCI Insight. 2016;19:e87748.","journal-title":"JCI Insight"},{"issue":"1","key":"2615_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13287-019-1338-2","volume":"10","author":"J Gao","year":"2019","unstructured":"Gao J, Cheng Y, Hao H, Yin Y, Xue J, Zhang Q, et al. Decitabine assists umbilical cord-derived mesenchymal stem cells in improving glucose homeostasis by modulating macrophage polarization in type 2 diabetic mice. Stem Cell Res Therapy. 2019;10(1):259.","journal-title":"Stem Cell Res Therapy"},{"issue":"2","key":"2615_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.kint.2019.02.020","volume":"96","author":"G Chen","year":"2019","unstructured":"Chen G, Chen H, Ren S, Xia M, Zhu J, Liu Y, et al. Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease. Kidney Int. 2019;96(2):409\u201320.","journal-title":"Kidney Int"},{"key":"2615_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.kint.2017.01.010","volume":"1","author":"L Zhang","year":"2017","unstructured":"Zhang L, Zhang Q, Liu S, Chen Y, Li R, Lin T, et al. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney Int. 2017;1:140\u201353.","journal-title":"Kidney Int"},{"issue":"12","key":"2615_CR39","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1210\/en.2014-1595","volume":"155","author":"Q Cao","year":"2014","unstructured":"Cao Q, Wang X, Jia L, Mondal AK, Diallo A, Hawkins GA, et al. Inhibiting DNA methylation by 5-Aza-2\u2019-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation. Endocrinology. 2014;155(12):4925\u201338.","journal-title":"Endocrinology"},{"key":"2615_CR40","doi-asserted-by":"publisher","first-page":"G989","DOI":"10.1152\/ajpgi.00032.2016","volume":"6","author":"K Li","year":"2016","unstructured":"Li K, Zhang X, Yang L, Wang XX, Yang DH, Cao GQ, et al. Foxp3 promoter methylation impairs suppressive function of regulatory T cells in biliary atresia. Am J Physiol Gastrointest Liver Physiol. 2016;6:G989\u201397.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"2615_CR41","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.coi.2012.10.004","volume":"24","author":"J Choi","year":"2012","unstructured":"Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol. 2012;24(6):651\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"2615_CR42","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1093\/rheumatology\/kem275","volume":"46","author":"ZK Wen","year":"2007","unstructured":"Wen ZK, Xu W, Xu L, Cao QH, Wang Y, Chu YW, et al. DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford, England). 2007;46(12):1796\u2013803.","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"2615_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1172\/JCI116576","volume":"92","author":"J Quddus","year":"1993","unstructured":"Quddus J, Johnson KJ, Gavalchin J, Amento EP, Chrisp CE, Yung RL, et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Investig. 1993;92(1):38\u201353.","journal-title":"J Clin Investig"},{"issue":"9","key":"2615_CR44","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/eji.1830200917","volume":"20","author":"H Yoshida","year":"1990","unstructured":"Yoshida H, Yoshida M, Merino R, Shibata T, Izui S. 5-Azacytidine inhibits the lpr gene-induced lymphadenopathy and acceleration of lupus-like syndrome in MRL\/MpJ-lpr\/lpr mice. Eur J Immunol. 1990;20(9):1989\u201393.","journal-title":"Eur J Immunol"},{"issue":"2","key":"2615_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2249.1997.tb08326.x","volume":"110","author":"M Mizugaki","year":"1997","unstructured":"Mizugaki M, Yamaguchi T, Ishiwata S, Shindo H, Hishinuma T, Nozaki S, et al. Alteration of DNA methylation levels in MRL lupus mice. Clin Exp Immunol. 1997;110(2):265\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"16","key":"2615_CR46","doi-asserted-by":"publisher","first-page":"e120880","DOI":"10.1172\/jci.insight.120880","volume":"3","author":"H Li","year":"2018","unstructured":"Li H, Tsokos MG, Bickerton S, Sharabi A, Li Y, Moulton VR, et al. Precision DNA demethylation ameliorates disease in lupus-prone mice. JCI Insight. 2018;3(16):e120880. https:\/\/doi.org\/10.1172\/jci.insight.120880.","journal-title":"JCI Insight."},{"issue":"3","key":"2615_CR47","first-page":"311","volume":"72","author":"K Schauenstein","year":"1991","unstructured":"Schauenstein K, Csordas A, Kromer G, Dietrich H, Wick G. In-vivo treatment with 5-azacytidine causes degeneration of central lymphatic organs and induces autoimmune disease in the chicken. Int J Exp Pathol. 1991;72(3):311\u20138.","journal-title":"Int J Exp Pathol"},{"issue":"10058","key":"2615_CR48","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(16)00578-X","volume":"388","author":"RM Sweeney","year":"2016","unstructured":"Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet (London, England). 2016;388(10058):2416\u201330.","journal-title":"Lancet (London, England)"},{"issue":"10122","key":"2615_CR49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet (London, England). 2018;391(10122):783\u2013800.","journal-title":"Lancet (London, England)"},{"key":"2615_CR50","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopha.2016.09.072","volume":"84","author":"X Huang","year":"2016","unstructured":"Huang X, Kong G, Li Y, Zhu W, Xu H, Zhang X, et al. Decitabine and 5-azacitidine both alleviate LPS induced ARDS through anti-inflammatory\/antioxidant activity and protection of glycocalyx and inhibition of MAPK pathways in mice. Biomed Pharmacother. 2016;84:447\u201353. https:\/\/doi.org\/10.1016\/j.biopha.2016.09.072.","journal-title":"Biomed Pharmacother."},{"issue":"8","key":"2615_CR51","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41374-019-0242-9","volume":"99","author":"SN Cui","year":"2019","unstructured":"Cui SN, Chen L, Yang YY, Wang YX, Li SN, Zhou T, et al. Activation of death-associated protein kinase 1 promotes neutrophil apoptosis to accelerate inflammatory resolution in acute respiratory distress syndrome. Lab Invest. 2019;99(8):1143\u201356.","journal-title":"Lab Invest"},{"key":"2615_CR52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1165\/rcmb.2014-0327OC","volume":"5","author":"BD Singer","year":"2015","unstructured":"Singer BD, Mock JR, Aggarwal NR, Garibaldi BT, Sidhaye VK, Florez MA, et al. Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation. Am J Respir Cell Mol Biol. 2015;5:641\u201352.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2615_CR53","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ajpath.2014.05.008","volume":"8","author":"J Thangavel","year":"2014","unstructured":"Thangavel J, Malik AB, Elias HK, Rajasingh S, Simpson AD, Sundivakkam PK, et al. Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury. Am J Pathol. 2014;8:2237\u201349.","journal-title":"Am J Pathol"},{"key":"2615_CR54","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1242\/jcs.170258","volume":"15","author":"J Thangavel","year":"2015","unstructured":"Thangavel J, Samanta S, Rajasingh S, Barani B, Xuan YT, Dawn B, et al. Epigenetic modifiers reduce inflammation and modulate macrophage phenotype during endotoxemia-induced acute lung injury. J Cell Sci. 2015;15:3094\u2013105.","journal-title":"J Cell Sci"},{"key":"2615_CR55","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000343030","volume":"4","author":"CJ Wu","year":"2013","unstructured":"Wu CJ, Yang CY, Chen YH, Chen CM, Chen LC, Kuo ML. The DNA methylation inhibitor 5-azacytidine increases regulatory T cells and alleviates airway inflammation in ovalbumin-sensitized mice. Int Arch Allergy Immunol. 2013;4:356\u201364.","journal-title":"Int Arch Allergy Immunol"},{"key":"2615_CR56","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.jaci.2011.12.963","volume":"6","author":"S Brand","year":"2012","unstructured":"Brand S, Kesper DA, Teich R, Kilic-Niebergall E, Pinkenburg O, Bothur E, et al. DNA methylation of TH1\/TH2 cytokine genes affects sensitization and progress of experimental asthma. J Allergy Clin Immunol. 2012;6:1602-10.e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"9746","key":"2615_CR57","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet (London, England). 2010;376(9746):1094\u2013108.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2615_CR58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0306-3623(98)00273-0","volume":"33","author":"H Kroger","year":"1999","unstructured":"Kroger H, Dietrich A, Gratz R, Wild A, Ehrlich W. The effect of tryptophan plus methionine, 5-azacytidine, and methotrexate on adjuvant arthritis of rat. Gen Pharmacol. 1999;33(2):195\u2013201.","journal-title":"Gen Pharmacol"},{"issue":"8","key":"2615_CR59","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/art.40877","volume":"71","author":"DM Toth","year":"2019","unstructured":"Toth DM, Ocsko T, Balog A, Markovics A, Mikecz K, Kovacs L, et al. Amelioration of autoimmune arthritis in mice treated with the DNA methyltransferase inhibitor 5\u2019-azacytidine. Arthritis Rheumatol. 2019;71(8):1265\u201375.","journal-title":"Arthritis Rheumatol"},{"issue":"10130","key":"2615_CR60","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet (London, England). 2018;391(10130):1622\u201336.","journal-title":"Lancet (London, England)"},{"issue":"10045","key":"2615_CR61","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","volume":"388","author":"HJ Willison","year":"2016","unstructured":"Willison HJ, Jacobs BC, van Doorn PA. Guillain\u2013Barre syndrome. Lancet (London, England). 2016;388(10045):717\u201327.","journal-title":"Lancet (London, England)"},{"key":"2615_CR62","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2119\/molmed.2013.00159","volume":"20","author":"MW Chan","year":"2014","unstructured":"Chan MW, Chang CB, Tung CH, Sun J, Suen JL, Wu SF. Low-dose 5-aza-2\u2019-deoxycytidine pretreatment inhibits experimental autoimmune encephalomyelitis by induction of regulatory T cells. Mol Med (Cambridge, Mass). 2014;20:248\u201356.","journal-title":"Mol Med (Cambridge, Mass)"},{"issue":"12","key":"2615_CR63","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/jcp.24641","volume":"229","author":"K Mangano","year":"2014","unstructured":"Mangano K, Fagone P, Bendtzen K, Meroni PL, Quattrocchi C, Mammana S, et al. Hypomethylating agent 5-Aza-2\u2019-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. J Cell Physiol. 2014;229(12):1918\u201325.","journal-title":"J Cell Physiol"},{"key":"2615_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jneuroim.2018.05.013","volume":"321","author":"P Fagone","year":"2018","unstructured":"Fagone P, Mazzon E, Chikovani T, Saraceno A, Mammana S, Colletti G, et al. Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis. J Neuroimmunol. 2018;321:41\u20138.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"2615_CR65","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88\u201398.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2615_CR66","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/j.1365-2141.2010.08557.x","volume":"153","author":"S Pilorge","year":"2011","unstructured":"Pilorge S, Doleris LM, Dreyfus F, Park S. The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases. Br J Haematol. 2011;153(5):664\u20135.","journal-title":"Br J Haematol"},{"issue":"4","key":"2615_CR67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/BF02135399","volume":"20","author":"F Sorm","year":"1964","unstructured":"Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia. 1964;20(4):202\u20133.","journal-title":"Experientia"},{"issue":"2","key":"2615_CR68","first-page":"99","volume":"10","author":"K Sula","year":"1987","unstructured":"Sula K, Nouza K, Madar J, Cihak A. Modulation of cell-mediated immunity with 5-azapyrimidine nucleosides. Czech Med. 1987;10(2):99\u2013108.","journal-title":"Czech Med"},{"issue":"1","key":"2615_CR69","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","volume":"116","author":"J Choi","year":"2010","unstructured":"Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1):129\u201339.","journal-title":"Blood"},{"issue":"1","key":"2615_CR70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-016-0281-2","volume":"9","author":"G Fransolet","year":"2016","unstructured":"Fransolet G, Ehx G, Somja J, Delens L, Hannon M, Muller J, et al. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. J Hematol Oncol. 2016;9(1):53.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2615_CR71","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.4049\/jimmunol.1502399","volume":"198","author":"ML Cooper","year":"2017","unstructured":"Cooper ML, Choi J, Karpova D, Vij K, Ritchey J, Schroeder MA, et al. Azacitidine mitigates graft-versus-host disease via differential effects on the proliferation of T effectors and natural regulatory T cells in vivo. J Immunol. 2017;198(9):3746\u201354.","journal-title":"J Immunol"},{"issue":"8","key":"2615_CR72","doi-asserted-by":"publisher","first-page":"e104022","DOI":"10.1371\/journal.pone.0104022","volume":"9","author":"N Uchida","year":"2014","unstructured":"Uchida N, Hsieh MM, Platner C, Saunthararajah Y, Tisdale JF. Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction. PLoS ONE. 2014;9(8):e104022.","journal-title":"PLoS ONE"},{"issue":"15","key":"2615_CR73","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1242\/jcs.170258","volume":"128","author":"J Thangavel","year":"2015","unstructured":"Thangavel J, Samanta S, Rajasingh S, Barani B, Xuan YT, Dawn B, et al. Epigenetic modifiers reduce inflammation and modulate macrophage phenotype during endotoxemia-induced acute lung injury. J Cell Sci. 2015;128(15):3094\u2013105.","journal-title":"J Cell Sci"},{"issue":"8","key":"2615_CR74","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ajpath.2014.05.008","volume":"184","author":"J Thangavel","year":"2014","unstructured":"Thangavel J, Malik AB, Elias HK, Rajasingh S, Simpson AD, Sundivakkam PK, et al. Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury. Am J Pathol. 2014;184(8):2237\u201349.","journal-title":"Am J Pathol"},{"issue":"10","key":"2615_CR75","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/j.pain.0000000000000296","volume":"156","author":"CR Hooijmans","year":"2015","unstructured":"Hooijmans CR, Geessink FJ, Ritskes-Hoitinga M, Scheffer GJ. A systematic review and meta-analysis of the ability of analgesic drugs to reduce metastasis in experimental cancer models. Pain. 2015;156(10):1835\u201344.","journal-title":"Pain"},{"issue":"6","key":"2615_CR76","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.","journal-title":"PLoS Biol"},{"issue":"12","key":"2615_CR77","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/sj.bmt.1703028","volume":"27","author":"F Ravandi","year":"2001","unstructured":"Ravandi F, Kantarjian H, Cohen A, Davis M, O\u2019Brien S, Anderlini P, et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001;27(12):1221\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"2615_CR78","first-page":"S32","volume":"11","author":"S Giralt","year":"1997","unstructured":"Giralt S, Davis M, O\u2019Brien S, van Besien K, Champlin R, de Vos D, et al. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia. 1997;11(Suppl 1):S32\u20134.","journal-title":"Leukemia"},{"issue":"11","key":"2615_CR79","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/bmt.2008.400","volume":"43","author":"SL De Padua","year":"2009","unstructured":"De Padua SL, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 2009;43(11):839\u201343.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2615_CR80","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/cncr.11184","volume":"97","author":"M de Lima","year":"2003","unstructured":"de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003;97(5):1242\u20137.","journal-title":"Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02615-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-020-02615-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02615-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:49:10Z","timestamp":1609980550000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02615-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2615"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02615-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"15 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}